



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Granisetron

Cat. No.:	HY-B0071		
CAS No.:	109889-09-0		
Molecular Formula:	C ₁₈ H ₂₄ N ₄ O		
Molecular Weight:	312.41		
Target:	5-HT Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (80.02 mM; ultrasonic and warming and heat to 60°C)																			
	<table border="1"> <thead> <tr> <th rowspan="2">Concentration</th> <th colspan="3">Mass</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>1 mM</td> <td>3.2009 mL</td> <td>16.0046 mL</td> <td>32.0092 mL</td> </tr> <tr> <td>5 mM</td> <td>0.6402 mL</td> <td>3.2009 mL</td> <td>6.4018 mL</td> </tr> <tr> <td>10 mM</td> <td>0.3201 mL</td> <td>1.6005 mL</td> <td>3.2009 mL</td> </tr> </tbody> </table>	Concentration	Mass			1 mg	5 mg	10 mg	1 mM	3.2009 mL	16.0046 mL	32.0092 mL	5 mM	0.6402 mL	3.2009 mL	6.4018 mL	10 mM	0.3201 mL	1.6005 mL	3.2009 mL
Concentration	Mass																			
	1 mg	5 mg	10 mg																	
1 mM	3.2009 mL	16.0046 mL	32.0092 mL																	
5 mM	0.6402 mL	3.2009 mL	6.4018 mL																	
10 mM	0.3201 mL	1.6005 mL	3.2009 mL																	
	Please refer to the solubility information to select the appropriate solvent.																			
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution 																			

BIOLOGICAL ACTIVITY

Description	Granisetron (BRL 43694) is a serotonin 5-HT ₃ receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.
IC₅₀ & Target	5-HT ₃ Receptor 17 μM (IC ₅₀)
In Vitro	In rat forestomach GR reduced 5-HT-evoked contractions at IC ₅₀ 17 /- 6 μM. In isolated rabbit heart, GR 0.003-0.03 nM dose-

dependently reduced s-HT tachycardia; at high levels GR reduced submaximal and maximal responses to 5-HT^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Leukocyte accumulation was dose-dependently inhibited by granisetron both at 6 and 72 h after induction of inflammation. Granisetron increased PGE(2) level at a lower dose (50 microg/pouch) but higher doses (100 and 200 microg/pouch) inhibited the release. At the same time, TNFalpha production was decreased by the lower dose and increased by higher doses of granisetron in a reciprocal fashion^[2]. The GTDS displayed non-inferiority to oral granisetron: complete control was achieved by 60% of patients in the GTDS group, and 65% in the oral granisetron group (treatment difference, -5%; 95% confidence interval, -13-3). Both treatments were well tolerated, the most common adverse event being constipation^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Sanger GJ, Nelson DR. Selective and functional 5-hydroxytryptamine₃ receptor antagonism by BRL 43694 (granisetron). *Eur J Pharmacol.* 1989 Jan 10;159(2):113-24.
- [2]. Maleki-Dizaji N, Eteraf-Oskouei T, Fakhrjou A, The effects of 5HT₃ receptor antagonist granisetron on inflammatory parameters and angiogenesis in the air-pouch model of inflammation. *Int Immunopharmacol.* 2010 Sep;10(9):1010-6.
- [3]. Boccia RV, Gordan LN, Clark G, Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA